The following analysts have issued research coverage on Protox Therapeutics. The opinions, estimates or forecasts regarding Protox's performance made by analysts are theirs alone and do not necessarily represent the opinions, forecasts or predictions of Protox or its management. Protox does not by its reference below or distribution imply its endorsement of or concurrence with such opinions, estimates or forecasts.

Versant Partners
Douglas W. Loe, Ph.D., MBA
dloe@versantpartners.com
416-849-5005

Loewen, Ondaatje, McCutcheon Limited
Connie S. Chen, PhD
cchen@lomltd.com
416-964-4448

What's New

February 25, 2010
Protox Revises Terms Of Private Placement

February 24, 2010
Protox To Present At The Third International Symposium On Focal Therapy And Imaging Of Prostate And Kidney Cancer

February 4, 2010
Protox Announces Private Placement

January 11, 2010
Protox Announces Positive Phase 2B BPH Results

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

Stock Quote

	LAST TRADE:	$0.435
	TRADE TIME:	1:44PM EST
	CHANGE:	$0.00 (0.00%)
	PREV CLOSE:	$0.435
	OPEN:	$0.435
	BID:	$0.435
	ASK:	$0.445